- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00262951
Chemoradiation in Locally Advanced Pancreatic Cancer
A Phase II Pilot Study of Multi-Agent Neo-Adjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Interferon alfa may interfere with the growth of tumor cells. Giving combination chemotherapy and radiation therapy together with interferon alfa before surgery may shrink the tumor so it can be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy and radiation therapy together with interferon alfa works in treating patients with locally advanced pancreatic cancer that cannot be removed by surgery.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
OBJECTIVES:
Primary
- Determine the effect of neoadjuvant chemoradiotherapy and interferon alfa on converting patients with locally advanced unresectable adenocarcinoma of the pancreas to resectability.
Secondary
- Determine the rate and severity of early and late toxic effects of these regimens in these patients.
- Improve surgical morbidity profile and overall survival of patients who undergo surgical resection.
- Determine overall and progression-free survival of patients treated with this regimen.
OUTLINE: This is an pilot, single center study.
- Part 1 (neoadjuvant therapy): Patients receive fluorouracil IV continuously over 24 hours on days 1-38; cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36; and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, and 38. Patients also undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients then undergo restaging. Patients with resectable disease undergo surgery, and 4-10 weeks later, proceed to part 2. Patients with unresectable disease proceed directly to part 2, 4 weeks after completion of neoadjuvant therapy.
- Part 2 (chemotherapy): Patients receive fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 56 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with unresectable disease undergo restaging after each course of fluorouracil. If the tumor subsequently becomes resectable, patients then undergo surgery.
After completion of study treatment, patients are followed periodically for 5 years and then annually thereafter.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient must have newly diagnosed computated tomography (CT) and endoscopic ultrasound(EUS) stage Tx-4, N0-1, M0 adenocarcinoma of pancreas according to the American Joint Committee on Cancer (AJCC) staging system. The following cell types will NOT be eligible: adenosquamous carcinoma, ampullary carcinoma, carcinoid tumor, cystadenocarcinoma, cystadenoma, distal common bile duct carcinoma, duodenal carcinoma, or islet cell carcinoma
- Treatment must begin within 60 days of diagnosis
- Must have locally advanced inoperable pancreatic cancer with no metastatic spread as determined by a baseline diagnostic CT scan of the chest, endoscopic ultrasound and CT scan with intravenous (IV) contrast (or MRI) of abdomen/pelvis, within 30 days prior to registration.
- No prior systemic chemotherapy or radiation therapy for pancreatic cancer
- Documented Eastern Cooperative Oncology Group (ECOG/Zubrod) performance status 0-1 within 14 days prior to registration
Adequate hematologic, renal and hepatic function as defined by the following laboratory values (completed within 14 days prior to registration)
- white blood cell (WBC) > 3,000 mm3
- absolute neutrophil count (ANC) > 1,500 mm3
- platelet count ≥ 100,000 mm3
- hemoglobin > 9.5 g/dl
- serum creatinine < 1.5 times institutional upper limit of normal (ULN)
- total bilirubin ≤ 3 mg/dl
- AST (SGOT) < 4.0 times institutional ULN
- ALT (SGPT) < 4.0 times institutional ULN
- alkaline phosphatase < 2.0 times institutional ULN
- Age ≥ 18 years
- Life expectancy ≥ 12 weeks
- Patient (male or female) of reproductive potential are required to use a medically acceptable contraception during treatment and for 3 months after the last dose of chemotherapy.
- Not pregnant or breastfeeding since the drugs used in this study are Pregnancy Category D: Clear evidence of risk in pregnancy. A negative pregnancy test is required within 7 days of registration if pre- or perimenopausal (i.e., last menstrual period within one year of registration)
If patient has a previous diagnosis of cancer, all of the following criteria must be met and documented in the patient's medical record:
- Patient has undergone potentially curative therapy for all prior malignancies.
- No evidence of prior malignancies for at least 5 years (except for successfully treated cervical carcinoma in situ, carcinoma in situ of the breast, or nonmelanoma skin cancer.
- No evidence of recurrence of any prior malignancy.
- Patient who is receiving chronic immunotherapy (e.g. prednisone or methotrexate) for collagen vascular disease or other chronic immunologic abnormality are not eligible.
- Not requiring one or more of the contraindicated medications
- Patient must be able to understand the potential risks and benefits associated with this study. Patient able to give informed consent and would likely to comply with the study parameters.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Pancreatic Adenocarcinoma Patients
Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).
|
administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
Otros nombres:
administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
Otros nombres:
administered at a dose of 175 mg/m^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
Otros nombres:
5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor.
Evaluation of the growth/regression of the tumor will be made as it relates to resectability.
Surgical exploration will start with a diagnostic laparoscopy.
If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed.
In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Patients in Whom Tumor Was Resectable
Periodo de tiempo: Up to 5 Years or Until Disease Progression
|
Tumor response is measured in terms of resectability, as measured by CT scan at 2 weeks after completion of each course.
A CT scan of the chest abdomen and pelvis will be performed in order to evaluate for the presence of metastatic disease.
If no metastatic disease, emphasis will be paid to the local tumor.
Evaluation of the growth/regression of the tumor will be made as it relates to resectability.
If potential for resection then surgery will be recommended.
This protocol will be followed after each cycle.
|
Up to 5 Years or Until Disease Progression
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall Survival
Periodo de tiempo: Up to 5 Years or Date of Death, Whichever Occurred First
|
In all patients, measured from the date of the patient's registration in this study, until the date of the patient's death or date last known alive (if observation was censored).
|
Up to 5 Years or Date of Death, Whichever Occurred First
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Edward W. Greeno, MD, Masonic Cancer Center, University of Minnesota
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Enfermedades del sistema endocrino
- Neoplasias del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias pancreáticas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Interferones
- Interferón-alfa
- Cisplatino
- Fluorouracilo
- Interferón alfa-2
- Interferón-alfa-1b
Otros números de identificación del estudio
- 2004LS060
- 0410M64346 (Otro identificador: IRB, University of Minnesota)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de pancreas
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre recombinant interferon alfa
-
AOP Orphan Pharmaceuticals AGPharmaEssentia Corporation (Co-Sponsor for USA)TerminadoPolicitemia veraAustria, Bulgaria, República Checa, Francia, Hungría, Polonia, Eslovaquia, Ucrania
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.TerminadoReceptor de estrógeno negativo | HER2/Neu Negativo | Receptor de progesterona negativo | Cáncer de mama triple negativo | Cáncer de mama anatómico en estadio IV AJCCEstados Unidos
-
National Heart, Lung, and Blood Institute (NHLBI)TerminadoEnfermedad cardiovascularEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoTumores cerebrales y del sistema nervioso centralEstados Unidos
-
Genzyme, a Sanofi CompanyAprobado para la comercializaciónEnfermedad por almacenamiento de glucógeno tipo II (GSD-II) | Enfermedad por deficiencia de maltasa ácida | Glucogenosis 2 | Enfermedad de Pompe (inicio tardío)Estados Unidos
-
ProtalixChiesi Farmaceutici S.p.A.TerminadoEnfermedad de FabryEstados Unidos, España, Reino Unido, Paraguay
-
ProtalixChiesi Farmaceutici S.p.A.TerminadoEnfermedad de FabryAustralia, Países Bajos, Reino Unido, Canadá, Chequia, Noruega, Eslovenia
-
ShireTerminadoEnfermedad de FabryEstados Unidos
-
Jonsson Comprehensive Cancer CenterAmgenTerminadoLinfoma | Leucemia | Anemia | Tumor sólido adulto no especificado, protocolo específico | Mieloma múltiple y neoplasia de células plasmáticas | Trastorno linfoproliferativo | Condición precancerosa/no malignaEstados Unidos
-
University of California, San FranciscoDuke UniversityReclutamientoEnfermedad de Wolman | MPS IVA | Enfermedad de Pompe de inicio infantil | Enfermedad de Gaucher, tipo 2 | MPS VI | MPS I | Enfermedad de Gaucher, tipo 3 | MPSII | Mps VIIEstados Unidos